Latest & greatest articles for prostate cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on prostate cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on prostate cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for prostate cancer

1. A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER)

A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER) A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER) - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. Get (...) . A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER) , , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Department of Radiation Oncology, University of California, Los Angeles, CA, USA. 2 Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York City, NY, USA. 3 Department of Medicine, Statistics Core, University of California, Los Angeles, CA, USA. 4 Department of Urology, Mayo Clinic, Rochester, MN, USA

2021 EvidenceUpdates

2. Apalutamide (Erleada) - for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC)

Apalutamide (Erleada) - for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) Published 18 January 2021 Statement of advice SMC2323 apalutamide 60mg film-coated tablets (Erleada®) Janssen-Cilag Ltd 4 December 2020 ADVICE: in the absence of a submission from the holder of the marketing authorisation apalutamide (Erleada®) is not recommended for use within NHSScotland. Indication under review: in adult men for the treatment of metastatic hormone-sensitive prostate cancer

2021 Scottish Medicines Consortium

3. Relugolix (Orgovyx) - To treat advanced prostate cancer

Relugolix (Orgovyx) - To treat advanced prostate cancer Drug Approval Package: ORGOVYX U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: ORGOVYX Company: Myovant Sciences GmbH Application Number: 214621 Approval Date: 12/18/2020 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review Files (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

2021 FDA - Drug Approval Package

4. Gallium 68 PSMA-11 - For detection and localization of prostate cancer

Gallium 68 PSMA-11 - For detection and localization of prostate cancer Drug Approval Package: GALLIUM GA 68 PSMA-11 U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: GALLIUM GA 68 PSMA-11 Company: University of California Los Angeles Application Number: 212642 Approval Date: 12/01/2020 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA

2021 FDA - Drug Approval Package

5. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent

EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID (...) : 10.1016/j.eururo.2020.09.042. Epub 2020 Nov 7. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent , , , , , , , , , , , , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Department of Urology, University Hospital, St. Etienne, France. Electronic address: nicolas.mottet@chu-st-etienne.fr. 2 Department of Urology, St. Antonius Hospital, Utrecht, The Netherlands. 3 Hasselt, Belgium. 4 Department

2021 EvidenceUpdates

6. Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer

) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 3 of 221 1 Recommendations Recommendations 1.1 Darolutamide with androgen deprivation therapy (ADT) is recommended, within its marketing authorisation, as an option for treating hormone-relapsed prostate cancer in adults at high risk of developing metastatic disease. It is recommended only if the company provides darolutamide according to the commercial arrangement (...) -and- conditions#notice-of-rights). Page 4 of 222 2 Information about darolutamide Information about darolutamide Marketing authorisation indication Marketing authorisation indication 2.1 Darolutamide (Nubeqa, Bayer) is indicated 'for the treatment of adult men with non-metastatic castration resistant prostate cancer who are at high risk of developing metastatic disease' . Dosage in the marketing authorisation Dosage in the marketing authorisation 2.2 The dosage schedule is available in the summary of product

2020 National Institute for Health and Clinical Excellence - Technology Appraisals

7. Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study

* Actions Androstenes / adverse effects Actions Disease-Free Survival Actions Humans Actions Male Actions Middle Aged Actions Neoplasm Metastasis Actions Phenylthiohydantoin / administration & dosage Actions Phenylthiohydantoin / adverse effects Actions Phenylthiohydantoin / analogs & derivatives* Actions Prostatic Neoplasms, Castration-Resistant / drug therapy* Actions Prostatic Neoplasms, Castration-Resistant / epidemiology Actions Prostatic Neoplasms, Castration-Resistant / pathology Actions Quality (...) Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study - PubMed This site needs JavaScript to work properly. Please enable it to take

2020 EvidenceUpdates

8. Darolutamide (Nubeqa) - non-metastatic castration resistant prostate cancer (nmCRPC)

submission darolutamide (Nubeqa®) is accepted for use within NHSScotland. Indication under review: Darolutamide is indicated for the treatment of adult men with non-metastatic castration resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease. In a phase III study in men with high risk nmCRPC, treatment with darolutamide was superior to placebo for metastasis-free survival. High risk was defined as prostate specific antigen (PSA) doubling time =10 months and PSA =2 (...) castration resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease. 1 Dosing Information The recommended dose of darolutamide is 600mg (two whole tablets of 300mg) taken orally, with food, twice daily, equivalent to a total daily dose of 1200mg. Medical castration with a luteinising hormone-releasing hormone (LHRH) analogue should be continued during treatment of patients not surgically castrated. If a dose is missed, the dose should be taken as soon as the patient

2020 Scottish Medicines Consortium

9. Olaparib (Lynparza) for metastatic castration-resistant prostate cancer (mCRPC)

Olaparib (Lynparza) for metastatic castration-resistant prostate cancer (mCRPC) Olaparib (Lynparza®) for metastatic castration-resistant prostate cancer (mCRPC) - Repository of AIHTA GmbH English | Browse - - - Olaparib (Lynparza®) for metastatic castration-resistant prostate cancer (mCRPC) Grössmann, N. (2020): Olaparib (Lynparza®) for metastatic castration-resistant prostate cancer (mCRPC). Oncology Fact Sheet Nr. 23. Preview - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z

2020 Austrian Institute of Health Technology Assessment

10. Apalutamide (prostate cancer) - Addendum to Commission A20-20

a CHAARTED RCT, open- label, parallel- group Adult patients with pathologically or clinically confirmed metastatic prostate cancer and ECOG-PS = 2 b Docetaxel + ADT (N = 397) ADT (N = 393) Screening: ND Treatment: until disease progression, withdrawal of informed consent, unacceptable toxicity, or ? For docetaxel: maximum of six 21-day cycles or ? For ADT: until the development of resistance c Follow-up observation: maximum of 10 days after randomization 343 centres in the USA 07/2006–ND Data cut-off (...) Apalutamide (prostate cancer) - Addendum to Commission A20-20 1 Translation of addendum A20-62 Apalutamid (Prostatakarzinom) – Addendum zum Auftrag A20-20 (Version 1.0; Status: 6 August 2020). Please note: Please note: This document was translated by an external translator and is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum 6 August 2020 1.0 Commission: A20-62 Version: Status: IQWiG

2020 Institute for Quality and Efficiency in Healthcare (IQWiG)

11. Apalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V

advice Due to the corona pandemic, no external experts were involved. IQWiG employees involved in the dossier assessment ? Annette Christoph ? Christiane Balg ? Sabine Ostlender ? Min Ripoll ? Ulrike Seay ? Dorothea Sow ? Sibylle Sturtz ? Volker Vervölgyi Keywords: Apalutamide, Prostatic Neoplasms – Castration-Resistant, Benefit Assessment, NCT01946204 Extract of dossier assessment A20-36 Version 1.0 Apalutamide (prostate cancer) 29 June 2020 Institute for Quality and Efficiency in Health Care (IQWiG (...) in favour of apalutamide + ADT in comparison with placebo + ADT. This results in a hint of lesser harm of apalutamide + ADT in comparison with watchful waiting + ADT. Overall, however, it is questionable whether the effect is actually to be attributed to the outcome category of AEs or whether it rather reflects the disease symptoms. The events occurring under the SOC comprised typical locoregional symptoms of prostate cancer, e.g. urinary retention and hydronephrosis. Probability and extent of added

2020 Institute for Quality and Efficiency in Healthcare (IQWiG)

12. Enzalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)

and scientific advice No advisor on medical and scientific questions was available for the present dossier assessment. IQWiG employees involved in the dossier assessment ? Selver Altin ? Christiane Balg ? Klaus Gossens ? Tatjana Hermanns ? Katharina Hirsch ? Florina Kerekes ? Min Ripoll ? Volker Vervölgyi Keywords: Enzalutamide, Prostatic Neoplasms – Castration-Resistant, Benefit Assessment, NCT02003924 Extract of dossier assessment A20-46 Version 1.0 Enzalutamide (prostate cancer) 12 August 2020 Institute (...) enzalutamide treatment. Treatment with enzalutamide + ADT was continued until radiographic disease progression or, if the investigator deemed it to be of clinical benefit, beyond said progression. Patients of either study arm who had failed to qualify or elected not to participate in the open- label enzalutamide extension phase discontinued treatment with the study drug and proceeded to follow-up observation. Extract of dossier assessment A20-46 Version 1.0 Enzalutamide (prostate cancer) 12 August 2020

2020 Institute for Quality and Efficiency in Healthcare (IQWiG)

13. Fifteen year quality of life outcomes in men with localised prostate cancer: population based Australian prospective study. Full Text available with Trip Pro

Prostate Cancer Care and Outcomes Study (PCOS).General health and disease specific quality of life were self-reported at seven time points over a 15 year period, using the 12-item Short Form Health Survey scale, University of California, Los Angeles prostate cancer index, and expanded prostate cancer index composite short form (EPIC-26). Adjusted mean differences were calculated with controls as the comparison group. Clinical significance of adjusted mean differences was assessed by the minimally (...) Fifteen year quality of life outcomes in men with localised prostate cancer: population based Australian prospective study. To assess treatment related changes in quality of life up to 15 years after diagnosis of localised prostate cancer.Population based, prospective cohort study with follow-up over 15 years.New South Wales, Australia.1642 men with localised prostate cancer, aged less than 70, and 786 controls randomly recruited from the New South Wales electoral roll into the New South Wales

2020 BMJ

14. Therapies for Clinically Localized Prostate Cancer

differences may be limited to men age 65 and older or those with intermediate-risk disease. Active monitoring using PSA-based monitoring probably results in little to no difference in all-cause or prostate cancer mortality compared with RP or EBR plus AD over 10 years. Metastases were infrequent, but AM probably results in a small increase compared with RP and EBR+AD. Effects may not vary by patient or tumor risk factors. Harms were lowest with AM compared with RP or EBR plus AD or AS versus photodynamic (...) cancer (CLPC) detected clinically rather than by prostate-specific antigen (PSA) screening, radical prostatectomy (RP) may reduce mortality and metastases more than watchful waiting (WW) but causes more harms. Mortality reductions may be limited to men age 65 and older and those with intermediate-risk disease. • Active monitoring (AM) probably results in little to no mortality difference versus RP or external beam radiation (EBR)+androgen deprivation (AD) in PSA-detected CLPC and may result in fewer

2020 Effective Health Care Program (AHRQ)

15. Abiraterone for treating metastatic prostate cancer

diagnosed high-risk metastatic hormone-sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT); metastatic castration-resistant prostate cancer (mCRPC) in adult men who are asymptomatic or mildly symptomatic after failure of ADT in whom chemotherapy is not yet clinically indicated; and metastatic castration-resistant prostate cancer (mCRPC) in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen. Subsidy status Generic (...) Abiraterone for treating metastatic prostate cancer '); } else { document.write(' '); } ACE | Abiraterone for treating metastatic prostate cancer Search > > Abiraterone for treating metastatic prostate cancer - Abiraterone for treating metastatic prostate cancer Published on 1 October 2020 Guidance Recommendations The Ministry of Health’s Drug Advisory Committee has recommended: Generic abiraterone acetate 250 mg tablet (Abiranat) in line with its registered indications for treating: newly

2020 Appropriate Care Guides, Agency for Care Effectiveness (Singapore)

16. Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data. (Abstract)

Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data. It is unclear whether adjuvant or early salvage radiotherapy following radical prostatectomy is more appropriate for men who present with localised or locally advanced prostate cancer. We aimed to prospectively plan a systematic review of randomised controlled trials (RCTs) comparing these radiotherapy (...) approaches.We used a prospective framework for adaptive meta-analysis (FAME), starting the review process while eligible trials were ongoing. RCTs were eligible if they aimed to compare immediate adjuvant radiotherapy versus early salvage radiotherapy, following radical prostatectomy in men (age ≥18 years) with intermediate-risk or high-risk, localised or locally advanced prostate cancer. We searched trial registers and conference proceedings until July 8, 2020, to identify eligible RCTs. By establishing

2020 Lancet

17. Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. (Abstract)

) in cohort A, 0.83 (95% CI, 0.11 to 5.98) in cohort B, and 0.55 (95% CI, 0.29 to 1.06) in the overall population.Among men with metastatic castration-resistant prostate cancer who had tumors with at least one alteration in BRCA1, BRCA2, or ATM and whose disease had progressed during previous treatment with a next-generation hormonal agent, those who were initially assigned to receive olaparib had a significantly longer duration of overall survival than those who were assigned to receive enzalutamide (...) Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. We previously reported that olaparib led to significantly longer imaging-based progression-free survival than the physician's choice of enzalutamide or abiraterone among men with metastatic castration-resistant prostate cancer who had qualifying alterations in homologous recombination repair genes and whose disease had progressed during previous treatment with a next-generation hormonal agent. The results of the final

2020 NEJM

18. Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide. (Abstract)

Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide. Darolutamide is a structurally distinct androgen-receptor inhibitor that is approved for the treatment of nonmetastatic, castration-resistant prostate cancer. In the planned primary analysis of a phase 3 trial, the median metastasis-free survival was significantly longer with darolutamide (40.4 months) than with placebo (18.4 months). The data for the analysis of overall survival were immature at the time (...) . The incidence of adverse events after the start of treatment was similar in the two groups; no new safety signals were observed.Among men with nonmetastatic, castration-resistant prostate cancer, the percentage of patients who were alive at 3 years was significantly higher among those who received darolutamide than among those who received placebo. The incidence of adverse events was similar in the two groups. (Funded by Bayer HealthCare and Orion Pharma; ARAMIS ClinicalTrials.gov number, NCT02200614

2020 NEJM

19. Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer

Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced (...) ):3042-3050. doi: 10.1200/JCO.20.00315. Epub 2020 Jul 24. Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer , , , , , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Memorial Sloan Kettering Cancer Center, New York, NY. 2 Department of Biostatistics and Bioinformatics, Duke University, Durham, NC. 3 The Ohio State University Comprehensive Cancer Center, The James Cancer Hospital

2020 EvidenceUpdates

20. Prostate Cancer Part 1: Diagnosis and Referral in Primary Care

Cancer Tips, Advice, and Support – Prostate Centre Canada – Canadian Cancer Society – Diagnostic Code: 185 (malignant neoplasm of prostate) Abbreviations CCO - Cancer Care Ontario DRE - digital rectal exam ERSPC - European Randomized Study of Screening for Prostate Cancer LUTS - lower urinary tract symptoms PSA - prostate specific antigen This guideline is based on scientific evidence current as of November 2017 (refer to Methodology ). The guideline was developed by the BC Cancer Primary Care (...) the age of 60 when they are diagnosed and most men will survive their prostate cancer. It is estimated that 1 in 29 men who are diagnosed with prostate cancer would be expected to die of the disease. The following risk factors are associated with an increased risk of prostate cancer and should be considered when assessing men who present with symptoms or with questions about testing: Men of African descent. Family history of prostate cancer (paternal side; first-degree relatives (i.e., father

2020 Clinical Practice Guidelines and Protocols in British Columbia